Findings

What do systematic reviews say?

8 questions · 8 findings · 3 reviews · Musculoskeletal

No studies found 2 · 25%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 25%Moderate 2 · 25%High 2 · 25%

Serious adverse events · people with chronic gout

Allopurinol showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Allopurinol for chronic gout 2014 · Cochrane Headline outcomes only
RR 1.93 [0.48, 7.8]
2 studies · 453 participants
Moderate

Number of participants experiencing any serious adverse events · patients with osteoarthritis

1 finding from 1 review

Tramadol for osteoarthritis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 15 participants
Low

Number of participants experiencing any serious adverse events · patients with osteoarthritis

1 finding from 1 review

Tramadol for osteoarthritis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 15 participants
Low

Number of participants experiencing any serious adverse events · patients with osteoarthritis

The review found no eligible studies for this question.

1 finding from 1 review

Tramadol for osteoarthritis 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Serious adverse events · people with chronic gout

Febuxostat 40 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
RR 0.61 [0.35, 1.07]
1 study · 1513 participants
High

Serious adverse events · people with chronic gout

Febuxostat 80 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (moderate certainty).

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
RR 0.91 [0.34, 2.4]
3 studies · 1044 participants
Moderate

Serious adverse events · people with chronic gout

Febuxostat 120 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
RR 1.2 [0.7, 1.93]
3 studies · 1041 participants
High

Number of participants experiencing any serious adverse events · patients with osteoarthritis

The review found no eligible studies for this question.

1 finding from 1 review

Tramadol for osteoarthritis 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found